Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status

BACKGROUND: The treatment of glioblastoma multiforme (GBM) is an unmet clinical need. The 5-year survival rate of patients with GBM is less than 3%. Temozolomide (TMZ) remains the standard first-line treatment regimen for gliomas despite the fact that more than 90% of recurrent gliomas do not respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Dawn Q, Toh, Xin Y, Ho, Ivy AW, Sia, Kian C, Newman, Jennifer P, Yulyana, Yulyana, Ng, Wai-Hoe, Lai, Siang H, Ho, Mac MF, Dinesh, Nivedh, Tham, Chee K, Lam, Paula YP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408574/
https://www.ncbi.nlm.nih.gov/pubmed/25886314
http://dx.doi.org/10.1186/s12885-015-1191-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408574/
https://www.ncbi.nlm.nih.gov/pubmed/25886314
http://dx.doi.org/10.1186/s12885-015-1191-3

Ejemplares similares